Reata Pharmaceuticals Inc (NASDAQ:RETA)
| 25.17 Delayed Data As of Sep 30 |  +0.14 / +0.56%Today’s Change | 18.47 Today|||52-Week Range 114.80 | -4.55% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $910.6M |
Company Description
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.
Contact Information
Reata Pharmaceuticals, Inc. 5320 Legacy Drive Plano Texas 75024 |
Employees
Shareholders
| Other institutional | 47.82% |
| Mutual fund holders | 29.59% |
| Individual stakeholders | 23.78% |
Top Executives
| J. Warren Huff | Chairman & Chief Executive Officer |
| Manmeet Singh Soni | President, Chief Operating & Financial Officer |
| W. Christian Wigley | Chief Scientific Officer & Senior Vice President |
| Edmund Doherty | Vice President-Medical Affairs |
| Samina Khan | Chief Medical Officer & Senior Vice President |
